Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 531-539

  Tong, Alex W ^a   Su, Dan ^a   Mues, Gabriele ^b   Tillery, G Weldon ^c   Goldstein, Robert ^c   Klintmalm, Goran ^c   Stone, Marvin J ^a,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIZATION; GRAFT REJECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER TRANSPLANTATION; PLASMA; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CYCLOSPORINE; CYCLOSPORINS; DOXORUBICIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; P-GLYCOPROTEIN;

EID: 0030000540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Gores, G. J., and Steers, J. L. Progress in orthotopic liver transplantation for hepatocellular carcinoma. Gastroenterology, 104: 317-319, 1993.
2. Stone, M., Klintmalm, G. B. G., Polter, D., Husberg, B. S , Mennel, R. G., Ramsay, M. A. E., Flemens, E. E., and Goldstein, R. M. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study of 20 patients. Gastroenterology, 104: 196-202, 1993.
3. Stone, M. J. Transplantation for primary hepatic malignancy. In: R. W. Busuttil and G. B. Klintmalm (eds.), Transplantation of the Liver. Philadelphia: W. B. Saunders, in press, 1996.
4. Gottesman, M. M. How cancer cells evade chemotherapy: 16th Richard and Hinda Rasenthal Foundation award lecture. Cancer Res., 53: 747-754, 1993.
5. Weinstein, R. S., Grogan, T. M., Kuszak, J. R., Jakate, S. M., Kluskens, L. F., and Coon, J. S. Multidrug resistance gene product (P-glycoprotein) in normal tissue and tumors. Adv. Pathol. Lab. Med., 91: 207-234, 1991.
6. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese Hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
7. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
8. Huang, C., Wu, M., Xu, G., Li, D., Cheng, H., Tu, Z., Jiang, H., and Gu, J. Overexpression of the mdr1 gene and P-glycoprotein in human hepatocellular carcinoma. J. Natl. Cancer Inst., 84: 262-264, 1992.
9. Chinivesse, X., Franco, D., and Brechot, C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J. Hepatol , 18: 168-172, 1993.
10. Itsubo, M., Ishikawa, T., Toda, G., and Tanaka, M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer (Phila.), 73: 298-303, 1994
11. Kim, J. H., Chung, J. B., Par, I. S., Kim, B. S., Yoo, N. C , Choi, J. H., Roh, J. K., Kim, H. S., Kwon, O. H., Lee, K. S., and Kim, B. S. Combined use of tamoxifen, cyclosporin A and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J., 34: 35-44, 1993.
12. Park, J. G., Lee, S. K., Hong, I. G., Kim, H. S., Lim, K. H. Choe, K. J., Kim, W. H., Kim, Y. I , Tsuruo, T., and Gottesman, M. M. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocelluar carcinoma cell lines. J. Natl. Cancer Inst., 86: 700-705, 1994.
13. Slater, L. M., Sweet, P , Stupecky, M., and Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin. Invest., 77: 1405-08, 1986.
14. Twentyman, P. R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol., 43: 109-117, 1992.
15. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
16. Herweijer, H., Sonneveld, P., Baas, F., and Nooter, K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. J. Natl. Cancer Inst., 82: 1133-1140, 1990.
17. Raderer, M., and Scheithauer, W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer (Phila.), 72: 3553-3563, 1993.
18. Speeg, K. V., and Maldonado, A. L. Effect of the non-immunosuppressive cyclosproin analog SDZ PSC-833 on colchicine and doxorubicin secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34: 133-136, 1994.
19. Simon, S. M., and Schindler, M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA, 91: 3497-3504, 1994.
20. Tong, A. W., Klintmalm, G., Su, D., and Stone, M. J. Enhancement of doxorubicin cytotoxicity by cyclosporin A in human multidrug-resistant hepatocellular carcinoma. Proc. Am. Assoc. Cancer Res., 35: 356, 1994.
21. Insert for TDx Immunosuppressant Drug Assays - Cyclosporine Monoclonal Whole Blood. Abbott Park, IL: Abbott Laboratories, 1993.
22. Tong, A. W., Lee, J. C., and Stone, M. J. Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies. J. Natl. Cancer Inst., 77: 1023-1033, 1986.
23. Hamada, H., and Tsuruo, T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 83: 7785-7789, 1986.
24. Scheper, R. J., Bulte, J. W. M., Brakkee, J. G. P., Quak, J. J., van der School, E., Balm, A. J., Meijer, C. J., Broxterman, H. J., Kuiper, C. M., and Lankelma, J. Monoclonal antibody JSB-I detects a highly conserved epitope on the P-glycoprotein asociated with multidrug resistance. Int. J. Cancer. 42: 389-394, 1988.
25. Tong, A. W., Zhang, B. Q., Mues, G., Solano, M., Hanson, T., and Stone, M. J Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood, 84: 3026-3033, 1994.
26. Tong, A. W., Lee, J. C., Wang, R. M., and Stone, M. J. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibody against human small cell lung carcinoma. Cancer Res., 49: 4103-4108, 1989.
27. National Academy of Clinical Biochemistry/American Association for Clinical Chemistry Task Force on Cyclosporine Monitoring. Critical issues in Cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin. Chem., 33: 1269-1288, 1987.
28. Kessel, D., Beck, W. T., Kukuruga, D., and Schulz, V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res., 51: 4665-4670, 1991.
29. Dietel, M , Heizy, I., Reyman, A., Brandt, I., Schaefer, B., Bunge, A., Heidebrecht, H. J., and Seidel, A. Secondary combined resistance to the multidrug-resistance reversing activity of cyclosporin A in the cell line F4-6RADR-CsA J. Clin. Res. Clin. Oncol., 120: 263-71, 1994.
30. Biedler, J. L. Drug resistance: genotype versus phenotype - 32nd G. H. A. Clowes Memorial award lecture. Cancer Res., 54: 666-678, 1994.
31. Verweij, J., Herweijer, H , Oosterom, R., van der Burg, M. E. L., Plantin, A. S. T., Seynaeve, C., Stoter, G., and Nooter, K. A phase II study of epidoxorubicin in colorectoal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br. J. Cancer, 64: 361-364, 1991.
32. Lum, B L., Fisher, G. A., Brophy, N. A. Yahanda, A. M , Adler, K. M., Kaubisch, S., Halsey, J., and Sikic, B. I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer (Phila.), 72 (Suppl.): 3502-3514, 1993.
33. List, A F., Spier, C., Greer, J , Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., and Dalton, W. Phase I/II trial of cyclsporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol , 11: 1652-1660, 1993.
34. Sonneveld, P., Dune, B. G , Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet, 340: 255-259, 1992
35. Speth, P A. J., Lissen, P. C. M., Holdzinet, R. S G., and Haanen, C. Cellular and plasma Adriamycin concentrations in patients with myeloma treated with 96-hour continuous infusion. Clin. Pharmacol. Ther., 41: 661-665, 1987.
36. Speth, P. A., van Hoesel, Q. G., and Haanen, C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacol., 15: 15-31, 1988.
37. Speth, P. A., Linssen, P. C., Beex, L. V., Boezeman, J. B., and Haanen, C. Cellular and plasma pharmacokinetics of weekly 20-mg 4′-epi-Adriamycin bolus injection in patients with advanced breast carcinoma. Cancer Chemother. Pharmacol., 18: 78-82, 1986.
38. Naito, M., Oh-hara, T , Yamazaki, A., Danki, T., and Tsuruo, T. Reversal of multidrug resistance by an immunosuppressive agent FK506. Cancer Chemother. Pharmacol., 29: 195-200, 1992.
39. Shaw, L. M., Yatscoff, R. W., Bowers, L. D., Freeman, D. J., Jeffery, J. R., Keown, P. A., McGilverary, I. J., Rosano, T. G., and Wong, P. Y. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin. Chem., 36: 1848-1846, 1990.
40. Van der Bliek, A. M., Baas, F., Ten Houle de Lange, T., Kooiman, P. M., Van der Velde-Koerts, T., and Borst, P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNA in liver. EMBO J., 3325-3331, 1987.
41. Grant, C. D., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C. and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
42. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.
43. Booser, D. J., and Hortobagyi, G. N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs, 47: 223-258, 1994.
44. Johnsson, B., Nilsson, K., Nygren, P., and Larsson, R. SDZ PSC 833 - a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs, 3: 641-646, 1992.
45. Pourtier-Manzanedo, A., Boesch, D., and Loor, F FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. Anticancer Drugs, 2: 279-283, 1991.
46. Klintmalm, G. A review of FK506: a new immunosuppressant agent for the prevention and rescue of graft rejection. Transplant. Rev., 8. 53-63, 1994.
47. Maurer, G., and LeMaire, M. Biotransformation and distribution in blood of cyclosporine and its metabolites Transplant. Proc., 18: 25-34, 1986.
48. Scheulen, M. E., Budach, W., Skorzec, M., Wiefelsputz, J. K., and Seeber, S. Influence of cyclosporin A on the pharmacokinetics and pharmacodynamics of doxorubicin. Proc. Am. Assoc. Cancer Res., 34: 213, 1993.
49. Iwatsuki, S., Starzl, T. E , Sheahan, D. G., Yokoyama, I., Demetris, A. J., and Todo, S. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann. Surg., 214: 221-228, 1991.